Intra-Cellular Therapies (NASDAQ:ITCI) Stock Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). In a filing disclosed on May 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Intra-Cellular Therapies stock on April 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Beiersdorf Aktiengesellschaft (OTCMKTS:BDRFF) on 5/2/2025.
• Purchased $1,001 – $15,000 in shares of Alkami Technology (NASDAQ:ALKT) on 4/30/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of DXC Technology (NYSE:DXC) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of DOW (NYSE:DOW) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of Zions Bancorporation, National Association (NASDAQ:ZION) on 4/29/2025.
• Purchased $1,001 – $15,000 in shares of O’Reilly Automotive (NASDAQ:ORLY) on 4/29/2025.
• Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 4/29/2025.
• Sold $1,001 – $15,000 in shares of Humana (NYSE:HUM) on 4/29/2025.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI opened at $131.87 on Thursday. The firm has a market capitalization of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The business’s 50-day moving average is $131.70 and its 200 day moving average is $111.13. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Institutional Investors Weigh In On Intra-Cellular Therapies

Institutional investors have recently modified their holdings of the company. Accredited Wealth Management LLC purchased a new position in Intra-Cellular Therapies during the 4th quarter valued at about $28,000. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Intra-Cellular Therapies by 124.3% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 133 shares during the period. GAMMA Investing LLC grew its holdings in shares of Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 240 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in Intra-Cellular Therapies during the 4th quarter worth approximately $96,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $97,000. 92.33% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on ITCI. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their target price for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $140.00 to $132.00 in a research report on Monday, February 24th. Eleven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $109.70.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.